Pomegranates: Do They Deliver on Health Promises?

Pomegranates have been scrutinized extensively for their potential roles in supporting weight loss, managing diabetes, alleviating chronic obstructive pulmonary disease (COPD), combating prostate cancer, easing osteoarthritis symptoms, and treating rheumatoid arthritis. The high-profile legal battl

Pomegranates have been scrutinized extensively for their potential roles in supporting weight loss, managing diabetes, alleviating chronic obstructive pulmonary disease (COPD), combating prostate cancer, easing osteoarthritis symptoms, and treating rheumatoid arthritis.

The high-profile legal battle between POM Wonderful, a prominent pomegranate juice producer, and the Federal Trade Commission escalated to the U.S. Court of Appeals, where it was ultimately denied Supreme Court review. In this pivotal ruling, judges determined that numerous advertisements from POM contained false or misleading statements. The company had promoted medical research suggesting that regular intake of their products could treat, prevent, or lower the risk of conditions such as heart disease, prostate cancer, and erectile dysfunction. The First Amendment does not shield deceptive advertising practices. This decision represented a significant setback for the company's billionaire proprietors, with the court stipulating that claims about treating or preventing diseases require substantiation through at least one randomized clinical trial.

Examining the broader medical literature on pomegranates reveals numerous review articles highlighting their diverse health advantages, often accompanied by illustrative diagrams depicting the fruit's medicinal properties.

However, a closer inspection uncovers that these claims frequently rely on preliminary research, such as investigations into the antiobesity properties of pomegranate leaf extract in mouse models. This prompts two key questions: who consumes pomegranate leaves in practice, and how relevant are findings from mice to human physiology?

When assessing whether pomegranate intake influences human body weight, a comprehensive analysis of all available randomized controlled clinical trials—studies conducted directly on people—demonstrates no meaningful impact on body weight, body mass index (BMI), abdominal fat accumulation, or overall body fat percentage among participants assigned to pomegranate-based interventions.

Regarding the role of pomegranates in preventing or treating cardiovascular conditions, experts systematically evaluated 25 clinical trials. These examined key metrics including cholesterol levels, blood pressure, arterial functionality, the development of atherosclerotic plaques, and platelet activity. Even the most robust studies among them failed to reveal substantial benefits.

POM Wonderful sponsored research exploring pomegranate juice's effects on erectile dysfunction, yet the results were underwhelming and inconclusive. Similarly, additional investigations reported no improvements in diabetes-related biomarkers and showed no positive outcomes for chronic obstructive pulmonary diseases like emphysema. Proponents had anticipated benefits from the juice's antioxidant properties, but these were primarily observed in vitro, within controlled lab environments such as test tubes or petri dishes.

Surprisingly, a meta-analysis aggregating data from 11 randomized controlled trials concluded there is no compelling evidence that pomegranate consumption substantially elevates total antioxidant capacity in human blood. This may stem from the fact that some of the most powerful antioxidants in pomegranates are not effectively absorbed into the bloodstream. Consequently, pomegranate supplements failed to influence oxidative stress markers in tissue biopsies from prostate cancer patients. Ultimately, the critical question remains whether pomegranates impact cancer progression itself.

The most persuasive evidence for pomegranates' anticancer potential is purportedly derived from prostate cancer research. Regrettably, initial encouraging findings did not hold up under rigorous testing. For instance, a randomized controlled trial revealed that daily pomegranate consumption exerted no effect on prostate-specific antigen (PSA) levels, a vital indicator of tumor advancement. Furthermore, a randomized, double-blind, placebo-controlled study detected virtually no disparity in prostate cancer progression rates between treatment and placebo groups.

Researchers had hoped the anti-inflammatory qualities of pomegranate juice would prove beneficial, but these effects were again confined to in vitro settings. In human subjects, a 2016 meta-analysis of five randomized controlled trials determined that pomegranate juice does not significantly alter C-reactive protein levels, a primary inflammation indicator. Nonetheless, examining the forest plot from this analysis shows a consistent trend across all five studies toward reduced C-reactive protein, with combined results nearly achieving statistical significance.

A more recent 2020 meta-analysis, incorporating seven studies, surpassed the threshold for statistical significance, documenting notable reductions in C-reactive protein alongside two additional inflammatory markers.

These developments suggest pomegranate juice might indeed assist in managing inflammatory conditions, though definitive confirmation requires further clinical validation.

Osteoarthritis entails the progressive breakdown of protective cartilage in joints, most commonly affecting the knees. Laboratory experiments involving the application of pomegranate extract directly onto human osteoarthritic cartilage specimens indicated protective effects against degradation. Compared to baseline cartilage breakdown rates, inflammatory agents tripled the damage, but escalating doses of pomegranate extract progressively mitigated this deterioration.

Such results, however, are limited to petri dish simulations. For real-world applicability, the bioactive compounds must enter the bloodstream upon consumption and reach the joints. Studies in rabbits confirmed the bioavailability of cartilage-protective elements from pomegranates, hinting at their potential as a safe, side-effect-free alternative to conventional medications. Yet, efficacy in humans demanded clinical proof.

The inaugural human trial on pomegranate juice for osteoarthritis lacked a placebo control, instead assigning participants randomly to juice or no intervention. Juice consumers noted reduced stiffness and improved physical function, but these gains were not statistically superior to the no-treatment group.

On the verge of dismissing pomegranates entirely, attention turned to a study on hydrolyzable tannin-rich pomegranate extract suppressing inflammation and joint damage in rheumatoid arthritis models. Disappointingly, this research originated from POM Wonderful and utilized mice with induced joint damage to mimic the disease.

An open-label trial involved eight rheumatoid arthritis patients knowingly receiving daily pomegranate extract; six completers reported fewer tender joints. Without a control group, however, it remains unclear whether the extract or natural fluctuations drove these changes.

At last, a randomized, double-blind, placebo-controlled trial provided rigorous evidence. Participants were blindly allocated to pomegranate extract or a placebo equivalent. The pomegranate group exhibited marked improvements over placebo in swollen joint count, tender joint count, pain severity, disease activity scores, health assessment questionnaires, and morning stiffness duration. For individuals with rheumatoid arthritis, incorporating pomegranates into the diet merits serious consideration. Rather than relying on supplements—especially given that lab tests of 19 commercial pomegranate products found only six genuinely contained pomegranate—the whole fruit offers a reliable option.